Genetic determinants of statin-associated myopathy

Personalized Medicine

Volumn 5, Issue 5, 2008, Pages 481-494

  Molokhia, Mariam ^a   Bhatia, Simmi ^a   Nitsch, Dorothea ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Genetic polymorphisms; Rhabdomyolsis; SNP; Statin Induced myopathy

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN A; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 2; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SEROTONIN RECEPTOR; SIMVASTATIN; UBIDECARENONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CREATINE KINASE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSPORT; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; MONOTHERAPY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM;

EID: 56149123480     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.5.5.481     Document Type: Review

References (59)

1. Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis, of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267-1278 (2005).
2. The SEARCH Collaborative Group: SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Engl. J. Med. (2008) (Epub ahead of print).
3. Antons KA, Williams CD, Baker SK, Phillips PS: Clinical perspectives of statin-induced rhabdomyolysis. Am. J. Med. 119(5), 400-409 (2006).
4. Ballantyne CM, Corsini A, Davidson MH et al.: Risk for myopathy with statin therapy in high-risk patients. Arch. Inter. Med. 163(5), 553-564 (2003).
5. Gaist D, Rodriguez LA, Huerta C, Hallas J. Sindrup SH: Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 12(5), 565-569 (2001).
6. McClure DL, Valuck RJ, Gtanz M, Murphy JR, Hokanson JE: Statin and statin-fibrate use was significantly associated with increased nryositis risk in a managed care population. J. Clin. Epidemiol. 60(8), 812-818 (2007).
7. Kashani A, Phillips CO, Foody JM et al.: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114(25), 2788-2797 (2006).
8. Bradford RH, Shear CL, Chremos AN et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am. J Cardiol. 74(7), 667-673 (1994).
9. de Lemos JA, Blazing MA, Wiviott SD et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292(11), 1307-1316 (2004).
10. Soininen K, Niemi M, Kilkki E, Strandberg T, Kivisto KT: Muscle symptoms associated with statins: a series of twenty patients. Basic Clin. Pharmacal. Taxicol. 98(l), 51-54 (2006).
11. Vladutiu GD, Simmons Z, Isackson PJ et al.: Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle New 34(2), 153-162 (2006).
12. Downs JR, Clearfield M, Weis S et al.: Primary prevention of acute coronary events with lavastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279(20), 1615-1622 (1998).
13. Graham DJ, Staffa JA, Shatin D et al.: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292(21), 2585-2590 (2004).
14. Garcia-Rodriguez LA, Gonzalez EM, Wallander MA, Johansson S: The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol. Drug Saf. (2008) (Epub ahead of print).
15. Molokhia M, McKeigue P, Curcin V, Majeed A: Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class using case-crossover approach from 1991-2006. PLoS ONE 3(6), E2522 (2008).
16. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (9326), 7-22 (2002).
17. Sever PS, Dahlof B, Poulter NR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (9364). 1149-1158 (2003).
18. Stafta JA, Chang J, Green L: Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 346(7), 539-540 (2002).
19. Clayton D, McKeigue PM: Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 358(9290). 1356-1360 (2001).
20. Molokhia M. McKeigue P: EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. Pharmacogenomics 7(4), 633-638 (2006).
21. Wilke RA, Lin DW, Roden DM et al.: Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov. 6(11), 904-916 (2007).
22. Hoggart CJ, Parra EJ, Shriver MD et al.: Control of confounding of genetic associations in stratified populations. Am. J. Hum. Genet. 72(6), 1492-1504 (2003).
23. Pritchard JK, Stephens M, Rosenberg NA, Donnelly P: Association mapping in structured populations. Am. J. Hum. Genet. 67(1), 170-181 (2000).
24. Fiegenbaum M, da Silveira FR, van der Sand CR et al.: the role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Ther. 78(5), 551-558 (2005).
25. Zuccaro P, Mombelli G, Calabresi L, Baidassarre D, Palmi I, Sirtori CR. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol. Res. 55(4), 310-317 (2007).
26. Frudakis TN, Thomas MJ, Ginjupalli SN, Handelin B, Gabriel R, Gomez HJ: CYP2D6*4polymorphism is associated with statin-induced muscle effects. Pharmacogenet. Genomics 17(9), 695-707 (2007).
27. Prueksaritanont T, Ma B, Yu N: The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br. J. Clin. Pharmacol. 56(1), 120-124 (2003).
28. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80(6), 565-581 (2006).
29. Kivisto KT, Kantola T, Neuvonen PJ: Different effects of itraconazole on the pharmacokinetics of fluvastatin and lavastatin. Br. J. Clin. Pharmacol. 46(1) 48-53 (1998)
30. Neuvnoen PJ. kantola T. Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. 63(3), 332-341 (1998).
31. Hirano M, Maeda K, Shitara Y, Sugiyama Y: Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Dispos. 34(7), 1229-1236 (2006).
32. Ho RH, Kim RB: Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78(3), 260-277 (2005).
33. Hermann M, Bogsrud ME Molden E et al.: Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin. Pharmacol. Ther. 79(6), 532-539 (2006).
34. Rubio JC, Garcia-Consuegra I, Nogales-Gadea G et al.: A proposed molecular diaghoitic flowchart for myophosphorylase deficiency (McArdle disease) in blood samples from Spanish patients. Hum. Mutat. 28(2), 203-204 (2007).
35. Taroni F, Verderio E, Dworzak F, Willems PJ, Cavadini P, DiDonato S: Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patients. Nat. Genet. 4(3), 314-320 (1993).
36. Vladutiu GD, Bennett MJ, Smail D, Wong LJ, Taggart RT, Lindsley HB: A variable myopathy associated with heterozygosity for the R503C mutation in the carnitine palmitoyltransferase II gene. Mol. Genet. Metab. 70(2). 134-141 (2000).
37. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA: Genetic determinants of statin intolerance. Lipids Health Dis. 6, 7(2007).
38. Ruano G, Thompson PD, Windemuth A et al.: Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle New 36(3), 329-335 (2007).
39. Serruys PW, de Feyter F, Macaya C et al.: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287(24), 3215-3222 (2002).
40. Garsa AA, McLeod HL, Marsh S: CYP3A4 and CYP3A5 genotyping by pyrosequencing. BMC Med. Genet. 6,19 (2005).
41. Liu CH, Peck K, Huang JD et al.: Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. pharmagenomics 6(7) 731-747 (2005)
42. Kuel P, Zhang J, Lin Y. et al.: Sequence devesity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001).
43. Thompson EE. Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, di Rienzo A: CYP3A variation and the evolution of salt-sensitivity variants. Am. J. Hum. Genet. 75(6). 1059-1069 (2004).
44. Cavaco I, Piedade R, Gil JP, Ribeiro V: CYP2C8 polymorphism among the Portuguese. Clin. Chem. Lab. Med. 44(2) 168-170 (2006).
45. Muthiah YC, Lee WL, Teh LK, Ong CE, Ismail R: Genetic polymorphism of CYP2C8 in three Malaysian ethnics: CYP2C8*2 and CYP2C8*3 are found in Malaysian Indians. J. Clin. Pharm. Ther. 30(5), 487-490 (2005).
46. Rower S, Bienzie U, Weise A et al.: Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in northern Ghana. Trop. Med. Int. Health 10(12), 1271-1273 (2005).
47. Dreisbach AW, Japa S, Sigel A et al.: The prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am. J. Hypertens. 18(10), 1276-1281 (2005).
48. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E: Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol. Res. 50(2), 195-200 (2004).
49. Yang JQ, Morin S, Verstuyft C et al.: Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam. Clin. Pharmacol. 17(3), 373-376 (2003).
50. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M: Genetic paymorphisin of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol. 52(4), 447-450 (2001).
51. Zhao F. Loke C, Rankin SC et al.: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther. 76(3), 210-219 (2004).
52. Lee SY, Sohn KM, Ryu JY, Yoon YR, Shin JG, Kim JW. Sequence-based CYP2D6 genotyping in the Korean population. Ther. Drug Monit. 28(3), 382-387 (2006).
53. Bradford LD: CYP2D6 allele frequency in European Caucasians, Asians. Africans and their descendants. Pharmacogenomics 3(2), 229-243 (2002).
54. Tirona RG, Leake BE Merino G, Kim RB: Polymorphisms in OATP-C. identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J. Biol. Chem. 276(38), 35669-35675 (2001).
55. Nishiato Y, leiri I, Suzuki H et al.: Polymorphisms of OATP-C(SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73(6), 554-565 (2003).
56. Komoto C, Nakamura, T, Sakaeda T et al.: MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab. Pharmacokinet. 21(2), 126-132 (2006).
57. Allabi AC, Horsmans Y, Issaoui B, Gala JL: Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a west black African population. Eur. J. Clin. Pharmacol. 61(2), 97-102 (2005).
58. Balram C, Sharma A, Sivathasan C, Lee EJ: Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br. J. Clin. Pharmacol. 56(1) 78-83 (2003).
59. Schaeffeler E, Eichelbaum M, Brinkmann U, et al.: Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 358(9279). 383-384 (2001).